leukaemia
Spotting Leukaemia
September 7, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, leukaemia, pharma, pharmaceutical
Leukaemia is a household name, but how much do we really understand about it? Not enough, says Bethany Torr, Campaigns …
FDA halts trial after first CAR T-associated patient death
September 6, 2017Research and Development CAR T, CAR-T, Cancer, FDA, cellectis, leukaemia, patient death, pharma, pharmaceutical
French clinical-stage biopharma firm Cellectis has received an order from the FDA to halt its study of CAR T therapy …
Pfizer’s leukaemia drug gets opposing regulatory decisions on either side of the Atlantic
August 18, 2017Medical Communications, Sales and Marketing Besponsa, Cancer, FDA, NICE, Pfizer, leukaemia, pharma, pharmaceutical
Pfizer has received a bittersweet bout of news as it emerges that its drug Besponsa (inotuzumab ozogamicin) has received approval …
Novartis CEO reasserts 2018 growth expectations, discusses Alcon and Sandoz future
July 18, 2017Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, biosimilars, biotech, healthcare, joe jimenez, leukaemia, pharma, pharmaceuticals
Novartis has reiterated its expectation of sales growth beginning in 2018, as well as a positive outlook for its Alcon …
Discovery of predictive protein signature births new leukaemia treatment hopes
April 12, 2017Research and Development leukaemia
Researchers have discovered a protein signature which has proven to be highly predictive of leukaemia and has given rise to …
Scotland recommends Janssen’s Imbruvica for leukaemia
April 11, 2017Manufacturing and Production, Sales and Marketing SMC, imbruvica, leukaemia
Janssen has been celebrating the news that its Imbruvica (ibrutinib) has been recommended by the Scottish Medicines Consortium (SMC) for …
Novartis investigational CAR-T therapy gets FDA priority review
March 30, 2017Sales and Marketing CTL019, FDA, Novartis, leukaemia
Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy CTL019 (tisagenlecleucel-T) has been awarded has been awarded priority review by …
Link discovered between immune system genes and leukaemia
February 6, 2017Research and Development, Sales and Marketing Bloodwise, ICR, leukaemia
Research coming out of The Institute of Cancer Research, and funded by charity Bloodwise, has found that people who inherit …
Phase 2 failure for Innate Pharma leukaemia drug
February 6, 2017Research and Development, Sales and Marketing Innate Pharma, leukaemia, lirilumab
Lirilumab, Innate Pharma’s acute myeloid leukaemia (AML) treatment, has failed to meet its primary end point in a recent Phase …
Personalised leukaemia vaccine shows promise in new trial
December 12, 2016Sales and Marketing leukaemia
A personalised cancer vaccine has proven to have significant efficacy in the treatment of acute myeloid leukaemia (AML), researchers at …
Novartis posts 82% remission rate in CAR T paediatric study
December 5, 2016Research and Development, Sales and Marketing CAR T, CAR-T, Novartis, leukaemia, paediatric
Novartis has released the results of its global, paediatric study of the treatment of leukaemia in children and young adults …
Teva’s drug to replace chemotherapy in acute leukaemia
November 21, 2016Medical Communications, Sales and Marketing Teva, chemotherapy, first line, first-line, leukaemia
Teva Pharmaceutical announced that their drug Trisenox has been given approval from the European Commission to become the first line …
Nordic Nanovector to collaborate with Heidelberg Pharma to develop leukaemia treatment
October 26, 2016Research and Development Nordic Nanovector, WILEX, heidelberg pharma, leukaemia
Nordic Nanovector has announced that they have formed a partnership with WILEX subsidiary, Heidelberg Pharma. Heidelberg Pharma specialises in the …
New treatment for leukaemia nullifies cancer cells
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boston, Cancer, Germany, Harvard, Mainz University, leukaemia
New research was able to demonstrate that a targeted drug-based inactivation of two chromatin regulators would interrupt the self-renewal of …
Gamida Cell receives Breakthrough Therapy Designation from FDA
October 12, 2016Research and Development Breakthrough Therapy Designation, FDA, Gamida Cell, leukaemia, lymphoma
Gamida Cell have been granted a Breakthrough Therapy Designation for their NiCord drug. NiCord has already passed through Phase I …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
